BIOMARKER:

FGFR2 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR2 amplification	Gastric Adenocarcinoma	FGFR2 amplification	Gastric Adenocarcinoma	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D
FGFR2 amplification	Colorectal Cancer	FGFR2 amplification	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D
FGFR2 amplification	Colorectal Cancer	FGFR2 amplification	Colorectal Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR2 amplification	Non Small Cell Lung Cancer	FGFR2 amplification	Non Small Cell Lung Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Gastric Adenocarcinoma	FGFR2 amplification	Gastric Adenocarcinoma	nintedanib Sensitive: D – Preclinical nintedanib Sensitive : D	nintedanib Sensitive: D – Preclinical nintedanib Sensitive : D